{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:58:34Z","timestamp":1791021514580,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021546","name":"Suez University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021546","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine how fetuin-A contributes to diagnosing and assessing MASLD severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty MASLD patients and fifty healthy control participants were involved in this retrospective case-control research. Abdominal ultrasonography, fibroscan with controlled attenuated parameter scan (CAP scan), laboratory investigation (including fetuin-A assessment), clinical examination, and history-taking were performed on every case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fetuin-A level was considerably higher in the Cases group (1154.85\u2009\u00b1\u2009629.89) than in the Control group (505.29\u2009\u00b1\u2009150.4) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Fetuin-A had significant validity in the prediction of MASLD at a cut-off &gt;\u2009702.5 with 82% sensitivity, 90% specificity, and 86% overall accuracy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>One possible marker for MASLD diagnosis could be fetuin-A. Furthermore, a substantial association between such marker and the severity of the disease as it revealed a significant correlation with ultrasound grading and fibroscan with controlled attenuated parameters.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>1- Pan African Clinical Trial Registry.<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Unique Identifying number\/registration ID: PACTR202309644280965.<\/jats:p>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?%20TrialID=26860\">https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=26860<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                    <jats:p>Registration Approval date: 21\/09\/2023.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>2- ClinicalTrials.gov<\/jats:italic>\n                      <\/jats:bold>\n                      .\n                    <\/jats:p>\n                    <jats:p>Unique Identifying number \/registration ID: NCT06097039.<\/jats:p>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06097039?cond=NCT06097039&amp;rank=1\">https:\/\/clinicaltrials.gov\/study\/NCT06097039?cond=NCT06097039&amp;rank=1<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                    <jats:p>Registration Approval date: 25\/10\/2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-024-03310-y","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T13:01:51Z","timestamp":1721307711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study"],"prefix":"10.1186","volume":"24","author":[{"given":"Mohamed M.","family":"Elhoseeny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badawy A.","family":"Abdulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa M.","family":"Elsharaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer M.","family":"Rashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-0035","authenticated-orcid":false,"given":"Amira A. A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"10","key":"3310_CR1","doi-asserted-by":"publisher","first-page":"e111551","DOI":"10.1371\/journal.pone.0111551","volume":"9","author":"K Dvorak","year":"2014","unstructured":"Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M, et al. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice-an exploratory case-control study. PLoS ONE. 2014;9(10):e111551.","journal-title":"PLoS ONE"},{"issue":"6","key":"3310_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"7","key":"3310_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of MASLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"key":"3310_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00247-014-3024-y","volume":"44","author":"J Deng","year":"2014","unstructured":"Deng J, Fishbein MH, Rigsby CK, Zhang G, Schoeneman SE, Donaldson JS. Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. Pediatr Radiol. 2014;44:1379\u201387.","journal-title":"Pediatr Radiol"},{"key":"3310_CR5","doi-asserted-by":"crossref","unstructured":"Zhou Y, Nie M, Zhou H, Mao F, Zhao L, Ding J, Jing X. Head-to-head comparison of three different US-based quantitative parameters for hepatic steatosis assessment: a prospective study. Abdom Radiol. 2024 May;13:1\u20130.","DOI":"10.1007\/s00261-024-04347-z"},{"key":"3310_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2020.11.004","volume":"88","author":"MA Icer","year":"2021","unstructured":"Icer MA, Y\u0131ld\u0131ran H. Effects of fetuin-A with diverse functions and multiple mechanisms on human health. Clin Biochem. 2021;88:1\u20130.","journal-title":"Clin Biochem"},{"key":"3310_CR7","doi-asserted-by":"publisher","first-page":"945287","DOI":"10.3389\/fcell.2022.945287","volume":"10","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Tilahun Muche Z, Behaile T, Mariam A, Mengie Ayele T, Mekonnen Agidew M, Teshome Azezew M, Abebe Zewde E, Dejenie A, T. and, Mengstie A, M. The structure, biosynthesis, and biological roles of fetuin-A: a review. Front cell Dev Biology. 2022;10:945287.","journal-title":"Front cell Dev Biology"},{"issue":"1","key":"3310_CR8","first-page":"3","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu S, Xiao J, Zhao Z, Wang M, Wang Y, Xin Y. Systematic review and meta-analysis of circulating fetuin-A levels in nonalcoholic fatty liver disease. J Clin Translational Hepatol. 2021;9(1):3.","journal-title":"J Clin Translational Hepatol"},{"issue":"4","key":"3310_CR9","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1097\/SR9.0000000000000035","volume":"6","author":"G Mathew","year":"2021","unstructured":"Mathew G, Agha R. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. IJS Short Rep. 2021;6(4):e35.","journal-title":"IJS Short Rep"},{"issue":"9403","key":"3310_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"KC Tan","year":"2004","unstructured":"Tan KC. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"issue":"4","key":"3310_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The MASLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354.","journal-title":"Hepatology"},{"issue":"3","key":"3310_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745\u201350.","journal-title":"Gastroenterology"},{"issue":"4","key":"3310_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2893.2011.01534.x","volume":"19","author":"M Sasso","year":"2012","unstructured":"Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan\u00ae: validation in chronic hepatitis C. J Viral Hepatitis. 2012;19(4):244\u201353.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"3310_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","volume":"16","author":"MC Wong","year":"2019","unstructured":"Wong MC, Huang JL, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia\u2013Pacific region. Nat Reviews Gastroenterol Hepatol. 2019;16(1):57\u201373.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"4","key":"3310_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cld.710","volume":"11","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Disease. 2018;11(4):92\u20134.","journal-title":"Clin Liver Disease"},{"key":"3310_CR16","doi-asserted-by":"crossref","unstructured":"Amoroso M, Augustin S, Moosmang S, Gashaw I. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. J Mol Med 2024 May 16:1\u20138.","DOI":"10.1007\/s00109-024-02448-2"},{"key":"3310_CR17","doi-asserted-by":"crossref","unstructured":"Patel K, Asrani SK, Fiel MI, Levine D, Leung DH, Duarte-Rojo A, Dranoff JA, Nayfeh T, Hasan B, Taddei TH, Alsawaf Y. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology. 2024 Mar 15:10\u201397.","DOI":"10.1097\/HEP.0000000000000842"},{"issue":"2","key":"3310_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/187221411799015372","volume":"5","author":"K Mori","year":"2011","unstructured":"Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discovery. 2011;5(2):124\u201346.","journal-title":"Recent Pat Endocr Metab Immune Drug Discovery"},{"issue":"5","key":"3310_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/ijo.2014.203","volume":"39","author":"JF Trepanowski","year":"2015","unstructured":"Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link between obesity and related complications. Int J Obes. 2015;39(5):734\u201341.","journal-title":"Int J Obes"},{"issue":"4","key":"3310_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2265.2011.04070.x","volume":"75","author":"HY Ou","year":"2011","unstructured":"Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol. 2011;75(4):450\u20135.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"3310_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/EJE-11-0864","volume":"166","author":"JW Haukeland","year":"2012","unstructured":"Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, L\u00f8berg EM, Haaland T, et al. Fetuin-A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2012;166(3):503\u201310.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3310_CR22","doi-asserted-by":"publisher","first-page":"E266","DOI":"10.1152\/ajpendo.00262.2017","volume":"314","author":"A Peter","year":"2018","unstructured":"Peter A, Kovarova M, Staiger H, Machann J, Schick F, K\u00f6nigsrainer A, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiology-Endocrinology Metabolism. 2018;314(3):E266\u201373.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"key":"3310_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. MASLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:1\u201320.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"3310_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhepr.2019.10.001","volume":"1","author":"P Ramadori","year":"2019","unstructured":"Ramadori P, Klag T, Malek NP, Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019;1(6):448\u201359.","journal-title":"JHEP Rep"},{"issue":"11","key":"3310_CR25","doi-asserted-by":"publisher","first-page":"e0260477","DOI":"10.1371\/journal.pone.0260477","volume":"16","author":"EH Nah","year":"2021","unstructured":"Nah EH, Cho S, Park H, Noh D, Kwon E, Cho HI. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: a retrospective cross-sectional study. PLoS ONE. 2021;16(11):e0260477.","journal-title":"PLoS ONE"},{"issue":"1","key":"3310_CR26","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1038\/s41598-024-56796-7","volume":"14","author":"EK Choe","year":"2024","unstructured":"Choe EK, Kang HY. The association between platelet-related parameters and nonalcoholic fatty liver disease in a metabolically healthy nonobese population. Sci Rep. 2024;14(1):6118.","journal-title":"Sci Rep"},{"issue":"8","key":"3310_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109\u201323.","journal-title":"Metabolism"},{"key":"3310_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1590\/S0004-28032012000100015","volume":"49","author":"MR Souza","year":"2012","unstructured":"Souza MR, Diniz MD, Medeiros-Filho JE, Ara\u00fajo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89\u201396.","journal-title":"Arq Gastroenterol"},{"issue":"1","key":"3310_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2012.03.127","volume":"166","author":"S Lim","year":"2013","unstructured":"Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDL\u2013cholesterol. Int J Cardiol. 2013;166(1):8\u201314.","journal-title":"Int J Cardiol"},{"key":"3310_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cca.2014.07.017","volume":"438","author":"K Kikkawa","year":"2015","unstructured":"Kikkawa K, Nakajima K, Shimomura Y, Tokita Y, Machida T, Sumino H, et al. Small dense LDL cholesterol measured by homogeneous assay in Japanese healthy controls, metabolic syndrome and diabetes patients with or without a fatty liver. Clin Chim Acta. 2015;438:70\u20139.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"3310_CR31","doi-asserted-by":"publisher","first-page":"e82092","DOI":"10.1371\/journal.pone.0082092","volume":"8","author":"W Cao","year":"2013","unstructured":"Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS ONE. 2013;8(12):e82092.","journal-title":"PLoS ONE"},{"key":"3310_CR32","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10620-012-2098-3","volume":"57","author":"P Charatcharoenwitthaya","year":"2012","unstructured":"Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:1925\u201331.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"3310_CR33","first-page":"712","volume":"25","author":"G Rodr\u00edguez","year":"2010","unstructured":"Rodr\u00edguez G, Gallego S, Breidenassel C, Moreno LA, Gottrand F. Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents? Nutr Hosp. 2010;25(5):712\u20137.","journal-title":"Nutr Hosp"},{"issue":"4","key":"3310_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.mpg.0000239995.58388.56","volume":"43","author":"HM Patton","year":"2006","unstructured":"Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43(4):413\u201327.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"3310_CR35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10787-021-00837-4","volume":"29","author":"O Sardana","year":"2021","unstructured":"Sardana O, Goyal R, Bedi O. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. Inflammopharmacology. 2021;29(4):1061\u201374.","journal-title":"Inflammopharmacology"},{"issue":"6","key":"3310_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1258\/acb.2010.010169","volume":"47","author":"Y Yilmaz","year":"2010","unstructured":"Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, et al. Serum fetuin A\/\u03b1 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem. 2010;47(6):549\u201353.","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"3310_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1515\/jbcr-2017-0015","volume":"10","author":"RS Komsa-Penkova","year":"2017","unstructured":"Komsa-Penkova RS, Golemanov GM, Radionova ZV, Tonchev PT, Iliev SD, Penkov VV. Fetuin-A\u2013alpha2-heremans-schmid glycoprotein: from structure to a novel marker of chronic diseases part 1. Fetuin-A as a calcium chaperone and inflammatory marker. J Biomedical Clin Res. 2017;10(2):90\u20137.","journal-title":"J Biomedical Clin Res"},{"issue":"3","key":"3310_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/liv.12478","volume":"35","author":"M Sato","year":"2015","unstructured":"Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int. 2015;35(3):925\u201335.","journal-title":"Liver Int"},{"issue":"3","key":"3310_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.amjms.2017.01.002","volume":"353","author":"K Peng","year":"2017","unstructured":"Peng K, Mo Z, Tian G. Serum lipid abnormalities and nonalcoholic fatty liver disease in adult males. Am J Med Sci. 2017;353(3):236\u201341.","journal-title":"Am J Med Sci"},{"issue":"3","key":"3310_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/nu12030673","volume":"12","author":"GH Lee","year":"2020","unstructured":"Lee GH, Peng C, Park SA, Hoang TH, Lee HY, Kim J, et al. Citrus peel extract ameliorates high-fat diet-induced MASLD via activation of AMPK signaling. Nutrients. 2020;12(3):673.","journal-title":"Nutrients"},{"issue":"8","key":"3310_CR41","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/ijerph17082735","volume":"17","author":"X Pan","year":"2020","unstructured":"Pan X, Kaminga AC, Chen J, Luo M, Luo J. Fetuin-A and Fetuin-B in non-alcoholic fatty liver disease: a meta-analysis and meta-regression. Int J Environ Res Public Health. 2020;17(8):2735.","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"3310_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1042\/CS20120542","volume":"125","author":"A Kahraman","year":"2013","unstructured":"Kahraman A, Sowa JP, Schlattjan M, Sydor S, Pronadl M, Wree A, et al. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci. 2013;125(8):391\u2013400.","journal-title":"Clin Sci"},{"key":"3310_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40618-020-01274-w","volume":"44","author":"T Filardi","year":"2021","unstructured":"Filardi T, Panimolle F, Tiberti C, Crescioli C, Lenzi A, Pallotta N, Morano S. Circulating levels of fetuin-A are associated with moderate\u2013severe hepatic steatosis in young adults. J Endocrinol Investig. 2021;44:105\u201310.","journal-title":"J Endocrinol Investig"},{"issue":"10","key":"3310_CR44","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1440-1681.13131","volume":"46","author":"TW Jung","year":"2019","unstructured":"Jung TW, Ahn SH, Shin JW, Kim HC, Park ES, Abd El-Aty AM, et al. Protectin DX ameliorates palmitate\u2010induced hepatic insulin resistance through AMPK\/SIRT 1\u2010mediated modulation of fetuin\u2010A and SeP expression. Clin Exp Pharmacol Physiol. 2019;46(10):898\u2013909.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"3310_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4274\/jcrpe.4532","volume":"9","author":"\u00dcG \u015eiraz","year":"2017","unstructured":"\u015eiraz \u00dcG, Do\u011fan M, Hatipo\u011flu N, Muhtaro\u011flu S, Kurto\u011flu S. Can fetuin-A be a marker for insulin resistance and poor glycemic control in children with type 1 diabetes mellitus? J Clin Res Pediatr Endocrinol. 2017;9(4):293.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"2","key":"3310_CR46","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.21608\/ejhm.2022.268968","volume":"89","author":"MA Awadein","year":"2022","unstructured":"Awadein MA, Makholof MA, Saleh SA, Salama MM, Hussein RM, El-Ansary AR. Assessment of serum Fetuin-A level in patients with MASLD and Chronic Hepatitis C. Egypt J Hosp Med. 2022;89(2):6282\u20138.","journal-title":"Egypt J Hosp Med"},{"issue":"7","key":"3310_CR47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/metabo12070625","volume":"12","author":"Q Etienne","year":"2022","unstructured":"Etienne Q, Lebrun V, Komuta M, Navez B, Thissen JP, Leclercq IA, Lanthier N. Fetuin-A in activated liver macrophages is a key feature of non-alcoholic steatohepatitis. Metabolites. 2022;12(7):625.","journal-title":"Metabolites"},{"key":"3310_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bcp.2019.05.011","volume":"166","author":"KY Lee","year":"2019","unstructured":"Lee KY, Lee W, Jung SH, Park J, Sim H, Choi YJ, et al. Hepatic upregulation of fetuin-A mediates acetaminophen-induced liver injury through activation of TLR4 in mice. Biochem Pharmacol. 2019;166:46\u201355.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3310_CR49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","volume":"20","author":"J Schw\u00e4rzler","year":"2024","unstructured":"Schw\u00e4rzler J, Grabherr F, Grander C, Adolph TE, Tilg H. The pathophysiology of MASLD: an immunometabolic perspective. Expert Rev Clin Immunol. 2024;20(4):375\u201386.","journal-title":"Expert Rev Clin Immunol"},{"key":"3310_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40618-020-01274-w","volume":"44","author":"T Filardi","year":"2021","unstructured":"Filardi T, Panimolle F, Tiberti C, Crescioli C, Lenzi A, Pallotta N, et al. Circulating levels of fetuin-A are associated with moderate\u2013severe hepatic steatosis in young adults. J Endocrinol Investig. 2021;44:105\u201310.","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"3310_CR51","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.2337\/diabetes.51.6.1876","volume":"51","author":"H Xu","year":"2002","unstructured":"Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS. Altered tumor necrosis factor-\u03b1 (TNF-\u03b1) processing in adipocytes and increased expression of transmembrane TNF-\u03b1 in obesity. Diabetes. 2002;51(6):1876\u201383.","journal-title":"Diabetes"},{"issue":"6","key":"3310_CR52","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/nu12061899","volume":"12","author":"AM Gonzalez-Gil","year":"2020","unstructured":"Gonzalez-Gil AM, Elizondo-Montemayor L. The role of exercise in the interplay between myokines, hepatokines, osteokines, adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: a review. Nutrients. 2020;12(6):1899.","journal-title":"Nutrients"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03310-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03310-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03310-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T14:02:56Z","timestamp":1721311376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03310-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03310-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Benha University Scientific Research and Publications Ethics Committee approved the study (Approval Number: 1.8.19201). All subjects were informed and gave their voluntary, written, informed consent. It is declared that: All methods were carried out in accordance with relevant guidelines and regulations. It was performed according to the recommendations of Good Clinical Practice and the Declaration of Helsinki (2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}